HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
US8741591B2
(en)
|
2009-10-09 |
2014-06-03 |
The Research Foundation For The State University Of New York |
pH-insensitive glucose indicator protein
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
EP2537933A1
(de)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
JP6329170B2
(ja)
|
2012-12-07 |
2018-05-23 |
ケモセントリックス,インコーポレイティド |
ジアゾールラクタム
|
EP3640375A3
(de)
*
|
2012-12-11 |
2020-07-29 |
Albert Einstein College of Medicine |
Verfahren zur rezeptorligandenidentifikation mit hohem durchsatz
|
ES2721168T3
(es)
|
2013-01-11 |
2019-07-29 |
Dingfu Biotarget Co Ltd |
Agentes para tratar tumores, uso y método de los mismos
|
MY176706A
(en)
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
KR20160013049A
(ko)
|
2013-06-03 |
2016-02-03 |
노파르티스 아게 |
항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
|
ES2749744T3
(es)
*
|
2013-09-11 |
2020-03-23 |
Medimmune Ltd |
Anticuerpos anti-B7-H1 para tratar tumores
|
AR097584A1
(es)
*
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗pd−1抗体並びにその治療及び診断のための使用
|
EP3049445A4
(de)
|
2013-09-24 |
2017-10-25 |
Medicenna Therapeutics, Inc. |
Interleukin-2-fusionsproteine und verwendungen davon
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
SI3049441T1
(sl)
*
|
2013-09-27 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Formulacije protiteles proti PD-L1
|
EP3060581A4
(de)
*
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoklonale antikörper und fragmente davon
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
KR20240017102A
(ko)
*
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
AU2014369982B2
(en)
|
2013-12-24 |
2019-04-18 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
WO2015108907A2
(en)
*
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
EP4079321A1
(de)
*
|
2014-01-15 |
2022-10-26 |
Kadmon Corporation, LLC |
Immunmodulatorische mittel
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
CA2974651A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
SG10202108879SA
(en)
|
2014-02-10 |
2021-09-29 |
Merck Patent Gmbh |
TARGETED TGFβ INHIBITION
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
PL3122745T3
(pl)
|
2014-03-24 |
2019-08-30 |
Novartis Ag |
Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych
|
US10150802B2
(en)
|
2014-04-24 |
2018-12-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
KR20170003692A
(ko)
|
2014-05-15 |
2017-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
|
DK3149042T3
(da)
|
2014-05-29 |
2019-11-04 |
Spring Bioscience Corp |
PD-L1-antistoffer og anvendelser deraf
|
US10987322B2
(en)
|
2014-06-06 |
2021-04-27 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
TWI687438B
(zh)
*
|
2014-07-03 |
2020-03-11 |
英屬開曼群島商百濟神州生物科技有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
ES2910446T3
(es)
|
2014-07-09 |
2022-05-12 |
Birdie Biopharmaceuticals Inc |
Combinaciones anti-PD-L1 para tratar tumores
|
EP3851111A1
(de)
*
|
2014-07-10 |
2021-07-21 |
Biothera, Inc. |
Beta-glucan in kombination mit antikrebsmitteln mit beeinflussung der tumormikroumgebung
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
US10428146B2
(en)
|
2014-07-22 |
2019-10-01 |
Cb Therapeutics, Inc. |
Anti PD-1 antibodies
|
EP3936145A1
(de)
*
|
2014-07-31 |
2022-01-12 |
The University Of Western Australia |
Verfahren zur identifizierung von immuntherapie-arzneimittel-kombinationen unter verwendung eines netzwerkansatzes
|
CN110964108B
(zh)
|
2014-08-05 |
2023-07-07 |
中美冠科生物技术(太仓)有限公司 |
抗pd-l1抗体
|
JP2017523213A
(ja)
|
2014-08-06 |
2017-08-17 |
ノバルティス アーゲー |
抗菌薬としてのキノロン誘導体
|
WO2016024228A1
(en)
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
|
CA2956126A1
(en)
|
2014-08-15 |
2016-02-18 |
Merck Patent Gmbh |
Sirp-alpha immunoglobulin fusion proteins
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
BR112017006203A2
(pt)
*
|
2014-09-30 |
2018-05-02 |
Intervet International B.V. |
anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
|
KR101619862B1
(ko)
*
|
2014-09-30 |
2016-05-12 |
주식회사 녹십자 |
간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP4029508A1
(de)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Behandlung von krebs mit tlr9-agonist und checkpoint-hemmern
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
US11242319B2
(en)
|
2014-11-05 |
2022-02-08 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
CN117143814A
(zh)
*
|
2014-11-17 |
2023-12-01 |
阿迪塞特治疗公司 |
工程化的γδ T细胞
|
RS63149B1
(sr)
|
2014-12-05 |
2022-05-31 |
Xyphos Biosciences Inc |
Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
|
CN113412818B
(zh)
|
2014-12-09 |
2022-11-04 |
瑞泽恩制药公司 |
具有人源化分化簇274基因的非人动物
|
SG11201704053WA
(en)
|
2014-12-16 |
2017-06-29 |
Novartis Ag |
Isoxazole hydroxamic acid compounds as lpxc inhibitors
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
CN105777906B
(zh)
*
|
2014-12-19 |
2019-04-23 |
苏州丁孚靶点生物技术有限公司 |
抗pd-l1全人抗体及其应用
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
TGFβR拮抗劑
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
EP3250588A1
(de)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Kryptische polypeptide und verwendungen davon
|
DK3254110T3
(da)
|
2015-02-03 |
2020-05-18 |
Ventana Med Syst Inc |
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
AU2016221305B2
(en)
|
2015-02-18 |
2021-05-27 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
RU2742312C1
(ru)
*
|
2015-02-26 |
2021-02-04 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
NZ733854A
(en)
*
|
2015-02-26 |
2022-07-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
TN2017000374A1
(en)
|
2015-03-02 |
2019-01-16 |
Bristol Myers Squibb Co |
TGF-β INHIBITORS
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
EP3067062A1
(de)
*
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
PE20171790A1
(es)
|
2015-03-23 |
2017-12-28 |
Bayer Pharma AG |
Anticuerpos anti-ceacam6 y sus usos
|
KR102610592B1
(ko)
*
|
2015-03-30 |
2023-12-07 |
주식회사 에스티큐브 |
당화 pd-l1에 특이적인 항체 및 그의 사용 방법
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
JP2018519245A
(ja)
|
2015-04-03 |
2018-07-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の治療のためのインドールアミン−2,3−ジオキシゲナーゼの阻害剤およびそれらの使用方法
|
US10842848B2
(en)
|
2015-04-07 |
2020-11-24 |
Cytlimic Inc. |
Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
CN107708811B
(zh)
|
2015-04-21 |
2021-04-30 |
恩立夫克治疗有限责任公司 |
治疗性汇集的血液凋亡细胞制剂与其用途
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
ES2815683T3
(es)
|
2015-05-11 |
2021-03-30 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como agentes antineoplásicos
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
ES2770349T3
(es)
|
2015-05-12 |
2020-07-01 |
Bristol Myers Squibb Co |
Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
|
US10945994B2
(en)
|
2015-05-14 |
2021-03-16 |
Pfizer Inc. |
Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
EP3303394B1
(de)
|
2015-05-29 |
2020-04-08 |
Agenus Inc. |
Anti-ctla-4-antikörper und verfahren zur verwendung davon
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
EP3302467A4
(de)
|
2015-05-31 |
2019-01-02 |
Curegenix Corporation |
Kombinationszusammensetzungen zur immuntherapie
|
KR20180038440A
(ko)
*
|
2015-06-09 |
2018-04-16 |
렉산 파마슈티컬스, 인코포레이티드 |
플루오로사이클로펜테닐시토신 용도 및 제조 방법
|
EP3307777A4
(de)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Neuartige anti-pd-l1-antikörper
|
CN106243225B
(zh)
*
|
2015-06-11 |
2021-01-19 |
智翔(上海)医药科技有限公司 |
新型抗-pd-l1抗体
|
US20180179282A1
(en)
|
2015-06-12 |
2018-06-28 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
WO2016205277A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
BR112017027653A2
(pt)
|
2015-06-29 |
2018-08-28 |
Ose Immunotherapeutics |
método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos
|
KR20180021833A
(ko)
|
2015-06-29 |
2018-03-05 |
더 락커펠러 유니버시티 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
MX2018000619A
(es)
|
2015-07-16 |
2019-03-06 |
Bioxcel Therapeutics Inc |
Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
|
KR20180034548A
(ko)
|
2015-07-28 |
2018-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3964528A1
(de)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen lag-3
|
EP4378957A2
(de)
|
2015-07-29 |
2024-06-05 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen pd-1
|
CN106397592A
(zh)
*
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
CN108349976A
(zh)
|
2015-08-25 |
2018-07-31 |
百时美施贵宝公司 |
TGFβ受体拮抗剂
|
KR20180049015A
(ko)
|
2015-09-04 |
2018-05-10 |
렉산 파마슈티컬스, 인코포레이티드 |
퀴녹살리닐-피페라진아미드의 사용 방법
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
CN106540255A
(zh)
*
|
2015-09-18 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
CN106565836B
(zh)
*
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
ES2892972T3
(es)
*
|
2015-11-02 |
2022-02-07 |
Univ Texas |
Métodos de activación de CD40 y bloqueo de punto de control inmunitario
|
KR20180071376A
(ko)
*
|
2015-11-17 |
2018-06-27 |
쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 |
Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도
|
TW202408573A
(zh)
|
2015-11-18 |
2024-03-01 |
美商必治妥施貴寶公司 |
使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
CN109152798B
(zh)
|
2015-12-02 |
2022-10-21 |
斯特库比股份有限公司 |
特异于糖基化的pd-1的抗体及其使用方法
|
NZ738202A
(en)
|
2015-12-03 |
2019-07-26 |
Glaxosmithkline Ip Dev Ltd |
Cyclic purine dinucleotides as modulators of sting
|
PT3386541T
(pt)
*
|
2015-12-07 |
2020-10-12 |
Merck Patent Gmbh |
Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
CN108602829A
(zh)
|
2015-12-15 |
2018-09-28 |
百时美施贵宝公司 |
Cxcr4受体拮抗剂
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
US20170198040A1
(en)
|
2015-12-18 |
2017-07-13 |
Novartis Ag |
ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
ES2919552T3
(es)
|
2015-12-23 |
2022-07-27 |
Modernatx Inc |
Procedimientos de utilización de polinucleotidos codificadores de ligando ox40
|
CN105461808B
(zh)
*
|
2015-12-24 |
2019-03-19 |
长春金赛药业股份有限公司 |
单克隆抗体及其应用
|
CN106939047B
(zh)
*
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
ES2839408T3
(es)
|
2016-01-13 |
2021-07-05 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
|
WO2017136562A2
(en)
*
|
2016-02-02 |
2017-08-10 |
Kadmon Corporation, Llc |
Bispecific binding proteins for pd-l1 and kdr
|
CA3014885A1
(en)
|
2016-02-18 |
2017-08-24 |
Enlivex Therapeutics Ltd. |
Combination immune therapy and cytokine control therapy for cancer treatment
|
CN109071447B
(zh)
|
2016-02-19 |
2022-04-22 |
诺华股份有限公司 |
四环吡啶酮化合物作为抗病毒剂
|
AU2017223846A1
(en)
|
2016-02-25 |
2018-08-23 |
Cell Medica Switzerland Ag |
Modified cells for immunotherapy
|
KR102068600B1
(ko)
|
2016-03-04 |
2020-01-21 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
Pdl-1 항체, 그 약학적 조성물 및 그 용도
|
EP3426271A4
(de)
|
2016-03-10 |
2019-10-16 |
Cold Genesys, Inc. |
Verfahren zur behandlung von soliden oder lymphatischen tumoren durch kombinationstherapie
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
CN107216389B
(zh)
*
|
2016-03-18 |
2022-03-29 |
和迈生物科技有限公司 |
抗pd-l1纳米抗体及其编码序列和用途
|
EP3433277A4
(de)
|
2016-03-23 |
2020-06-17 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Neuartige anti-pd-l1-antikörper
|
EP3433257B1
(de)
|
2016-03-24 |
2023-10-11 |
Novartis AG |
Alkynyl-nukleosid-analoga als inhibitoren des humanen rhinovirus
|
KR102367074B1
(ko)
|
2016-03-29 |
2022-02-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
|
EP3225253A1
(de)
|
2016-04-01 |
2017-10-04 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Krebstherapie mit einem onkolytischen, mit einem checkpoint-inhibitor kombinierten virus
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
JP2019510832A
(ja)
|
2016-04-07 |
2019-04-18 |
ケモセントリクス,インコーポレーテッド |
Pd−1阻害剤又はpd−l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減
|
CA3020830A1
(en)
|
2016-04-13 |
2017-10-19 |
Vivia Biotech, S.L |
Ex vivo bite.rtm. activated t cells
|
WO2017181073A1
(en)
*
|
2016-04-14 |
2017-10-19 |
Creatv Microtech, Inc. |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
KR102355240B1
(ko)
|
2016-04-14 |
2022-01-25 |
오제 이뮈노테라프틱스 |
신규한 항-SIRPa 항체 및 이들의 치료학적 적용 방법
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
CN105695406A
(zh)
*
|
2016-04-27 |
2016-06-22 |
天津普瑞赛尔生物科技有限公司 |
制备具有高效肿瘤杀伤性dc-cik免疫细胞的方法及制得的dc-cik免疫细胞
|
KR20190003685A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
KR20190003687A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
EP3452029A4
(de)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
Inhibitoren der indoleamin-2,3-dioxygenase und verfahren zu deren verwendung
|
CR20180521A
(es)
|
2016-05-05 |
2019-01-15 |
Glaxosmithkline Ip No 2 Ltd |
Inhibidores del potenciador del homólogo zeste 2
|
IL262295B2
(en)
*
|
2016-05-09 |
2023-09-01 |
Igm Biosciences Inc |
Antibodies against pd–l1
|
JP7210286B2
(ja)
|
2016-05-12 |
2023-01-23 |
アディセット バイオ, インコーポレイテッド |
γδT細胞集団の選択的増殖方法及びその組成物
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
CA3024917A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
RS63912B1
(sr)
|
2016-05-18 |
2023-02-28 |
Modernatx Inc |
Polinukleotidi koji kodiraju interleukin-12 (il12) i njihove upotrebe
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
IL263110B
(en)
|
2016-05-20 |
2022-07-01 |
Lilly Co Eli |
Combined treatment of notch and pd-1 or pd-l1 inhibitors
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
EP4248989A3
(de)
|
2016-06-02 |
2023-12-27 |
Bristol-Myers Squibb Company |
Pd-1 blockade mit nivolumab zur behandlung des refraktären hodgkin-lymphoms
|
US11083790B2
(en)
|
2016-06-02 |
2021-08-10 |
Bristol-Myers Squibb Company |
Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
|
JP2019517512A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
結腸直腸癌を有する患者の処置における抗pd−1抗体の使用
|
CN109476753A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗肿瘤的方法的抗-pd-1抗体
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
WO2017212425A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
US10077308B2
(en)
|
2016-06-13 |
2018-09-18 |
Askgene Pharma Inc. |
PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
|
PE20190510A1
(es)
|
2016-06-13 |
2019-04-10 |
I Mab |
Anticuerpos anti-pd-l1 y usos de los mismos
|
PL3468957T3
(pl)
|
2016-06-14 |
2021-01-25 |
Novartis Ag |
Krystaliczna postać (r)-4-(5-(cyklopropyloetynylo)izoksa-zol-3- ilo)- n-hydroksy-2-metylo-2-(metylosulfonylo)butano-amidu jako środek przeciwbakteryjny
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
JP7261379B2
(ja)
|
2016-06-20 |
2023-04-20 |
カイマブ・リミテッド |
抗pd-l1抗体
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CN109640999A
(zh)
|
2016-06-24 |
2019-04-16 |
无限药品股份有限公司 |
组合疗法
|
WO2017222556A2
(en)
|
2016-06-24 |
2017-12-28 |
Avidbiotics Corp. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
RU2749109C2
(ru)
|
2016-06-29 |
2021-06-04 |
Чекпойнт Терапьютикс, Инк. |
Специфические антитела к pd-l1 и способы их применения
|
BR112019000015A2
(pt)
|
2016-06-30 |
2019-04-24 |
Oncorus, Inc. |
distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
|
EP3481393B1
(de)
|
2016-07-05 |
2021-04-14 |
Beigene, Ltd. |
Kombination eines pd-1-antagonisten und eines raf-inhibitors zur behandlung von krebs
|
EP3507367A4
(de)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
|
CN117683135A
(zh)
|
2016-07-14 |
2024-03-12 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
WO2018015879A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
KR20190031299A
(ko)
|
2016-07-20 |
2019-03-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
ES2899036T3
(es)
*
|
2016-08-04 |
2022-03-09 |
Innovent Biologics Suzhou Co Ltd |
Nanocuerpo anti-PD-L1 y su uso
|
CN116640214A
(zh)
|
2016-08-09 |
2023-08-25 |
科马布有限公司 |
分离抗体及其应用
|
WO2018031507A1
(en)
*
|
2016-08-09 |
2018-02-15 |
Angimmune, Llc |
Treatment of cancer using a combination of immunomodulation and check point inhibitors
|
IL264730B1
(en)
*
|
2016-08-12 |
2024-05-01 |
Merck Patent Gmbh |
A pharmaceutical preparation containing TGFbetaRII and another anti-cancer preparation
|
TWI739887B
(zh)
|
2016-08-19 |
2021-09-21 |
英屬開曼群島商百濟神州有限公司 |
使用包含btk抑制劑的組合產品治療癌症
|
EP3504239B1
(de)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intervalldosierung eines anti-csf-1r-antikörpers in kombination mit makrophagenaktivierungsmittel
|
KR20190040990A
(ko)
|
2016-08-26 |
2019-04-19 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
CN106248955A
(zh)
*
|
2016-09-03 |
2016-12-21 |
长春工业大学 |
一种检测人源化pd‑l1抗体的试剂盒
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
AU2017322501A1
(en)
|
2016-09-09 |
2019-03-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
CN118005799A
(zh)
|
2016-09-23 |
2024-05-10 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
US11291718B2
(en)
|
2016-10-11 |
2022-04-05 |
Cytlimic Inc. |
Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
|
US10597454B2
(en)
|
2016-10-15 |
2020-03-24 |
Innovent Biologics (Suzhou) Co., Ltd |
PD-1 antibodies
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
EP3532504A1
(de)
|
2016-10-28 |
2019-09-04 |
Bristol-Myers Squibb Company |
Verfahren zur behandlung von urothelialem karzinom mit einem anti-pd-1-antikörper
|
AU2017348475B2
(en)
*
|
2016-10-30 |
2024-02-08 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-L1 antibodies and variants
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MX2019004775A
(es)
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018089688A1
(en)
|
2016-11-09 |
2018-05-17 |
Jinjun Shi |
Restoration of tumor suppression using mrna-based delivery system
|
CA3043124A1
(en)
*
|
2016-11-09 |
2018-05-17 |
Engene, Inc. |
Intestinal expression of programmed death ligand 1
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
CN106496327B
(zh)
*
|
2016-11-18 |
2019-01-15 |
昆山百尔泰生物科技有限公司 |
针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
CA3045243A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
EP3548069A1
(de)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
WO2018110515A1
(ja)
|
2016-12-12 |
2018-06-21 |
第一三共株式会社 |
抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
US10597438B2
(en)
|
2016-12-14 |
2020-03-24 |
Janssen Biotech, Inc. |
PD-L1 binding fibronectin type III domains
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
CN110225770B
(zh)
|
2016-12-14 |
2022-04-26 |
杨森生物科技公司 |
结合cd8a的纤连蛋白iii型结构域
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
CN110139922B
(zh)
|
2016-12-22 |
2021-05-25 |
香港大学 |
用于澄清组织的组合物和方法
|
IL297617B2
(en)
|
2016-12-22 |
2023-11-01 |
Cue Biopharma Inc |
Multimeric polypeptides modulate T cells and methods for their use
|
RU2766582C2
(ru)
*
|
2016-12-23 |
2022-03-15 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018129497A1
(en)
|
2017-01-09 |
2018-07-12 |
Bioxcel Therapeutics, Inc. |
Predictive and diagnostic methods for prostate cancer
|
EP3565829A4
(de)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
|
JP2020503883A
(ja)
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ny−eso−1に結合するt細胞受容体およびその使用方法
|
CN116768859A
(zh)
|
2017-01-20 |
2023-09-19 |
艾库斯生物科学有限公司 |
用于治疗癌症相关疾病的唑嘧啶
|
CN110461860A
(zh)
|
2017-01-24 |
2019-11-15 |
辉瑞公司 |
卡奇霉素衍生物及其抗体药物缀合物
|
HRP20220605T1
(hr)
|
2017-01-25 |
2022-07-08 |
Ose Immunotherapeutics |
Postupak za proizvodnju stabilne emulzije za isporuku peptida
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
US20190381157A1
(en)
*
|
2017-01-29 |
2019-12-19 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
HUE057337T2
(hu)
|
2017-02-10 |
2022-05-28 |
Novartis Ag |
1-(4-amino-5-bróm-6-(1H-pirazol-1-il)pirimidin-2-il)-1H-pirazol-4-ol és alkalmazása rák kezelésében
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
WO2018156888A1
(en)
|
2017-02-24 |
2018-08-30 |
Biothera Pharmaceuticals, Inc. |
Beta glucan immunopharmacodynamics
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
BR112019018401A2
(pt)
*
|
2017-03-06 |
2020-04-07 |
Merck Patent Gmbh |
formulação aquosa de anticorpo anti-pd-l1
|
EP3372615A1
(de)
|
2017-03-06 |
2018-09-12 |
Merck Patent GmbH |
Zusammensetzung mit avelumab
|
WO2018162749A1
(en)
|
2017-03-09 |
2018-09-13 |
Genmab A/S |
Antibodies against pd-l1
|
KR102619015B1
(ko)
|
2017-03-15 |
2023-12-28 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
CN110831963A
(zh)
*
|
2017-03-16 |
2020-02-21 |
高山免疫科学股份有限公司 |
Pd-l1变体免疫调节蛋白及其用途
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
US20200148785A1
(en)
*
|
2017-03-29 |
2020-05-14 |
Glycotope (GmbH) |
Pd-l1 and ta-muc1 antibodies
|
US20200048352A1
(en)
|
2017-03-30 |
2020-02-13 |
Merck Patent Gmbh |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
SG11201908396PA
(en)
|
2017-03-31 |
2019-10-30 |
Bristol Myers Squibb Co |
Methods of treating tumor
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
WO2018195283A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EP3612030A4
(de)
|
2017-04-21 |
2021-04-28 |
Ikena Oncology, Inc. |
Indol-ahr-inhibitor und verwendungen davon
|
WO2018200430A1
(en)
|
2017-04-26 |
2018-11-01 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
EP3618863B1
(de)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antikörper und deren verwendung
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
CN110050000B
(zh)
|
2017-05-12 |
2022-07-26 |
苏州盛迪亚生物医药有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP7274426B2
(ja)
|
2017-05-16 |
2023-05-16 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗gitrアゴニスト抗体での癌の処置
|
US11220492B2
(en)
|
2017-05-17 |
2022-01-11 |
Arcus Biosciences, Inc. |
Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
|
EP3625246A1
(de)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynukleotide zur codierung von gebundenen interleukin-12 (il12)-polypeptiden und verwendungen davon
|
CA3063715A1
(en)
|
2017-05-18 |
2018-11-22 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
EP4306542A3
(de)
|
2017-05-30 |
2024-04-17 |
Bristol-Myers Squibb Company |
Behandlung von lag-3-positiven tumoren
|
MX2019012076A
(es)
|
2017-05-30 |
2019-12-09 |
Bristol Myers Squibb Co |
Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
|
CA3060989A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
US11168144B2
(en)
|
2017-06-01 |
2021-11-09 |
Cytomx Therapeutics, Inc. |
Activatable anti-PDL1 antibodies, and methods of use thereof
|
CA3064331A1
(en)
|
2017-06-01 |
2018-12-06 |
Compugen Ltd. |
Triple combination antibody therapies
|
KR20200014363A
(ko)
|
2017-06-01 |
2020-02-10 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 종양을 치료하는 방법
|
WO2018223002A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd 123 cd3
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
BR112019025325A2
(pt)
|
2017-06-09 |
2020-06-23 |
Glaxosmithkline Intellectual Property Development Limited |
Métodos para tratar câncer, para fabricar um anticorpo anti-icos ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pdl1 ou porção de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou fragmento de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd-l1 ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, polinucleotídeo, vetor, e, célula hospedeira
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CA3067909A1
(en)
|
2017-06-19 |
2018-12-27 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
US20190048072A1
(en)
|
2017-06-22 |
2019-02-14 |
Novartis Ag |
USE OF IL-1beta BINDING ANTIBODIES
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
EP3645738A4
(de)
*
|
2017-06-25 |
2021-08-18 |
Systimmune, Inc. |
Anti-pd-l1-antikörper und verfahren zu ihrer herstellung und verwendung
|
CN110799543A
(zh)
|
2017-06-26 |
2020-02-14 |
百济神州有限公司 |
肝细胞癌的免疫治疗
|
AU2018291081A1
(en)
|
2017-06-27 |
2020-01-16 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
CN111093651B
(zh)
|
2017-06-30 |
2023-06-06 |
百时美施贵宝公司 |
Ido抑制剂的无定形和结晶形式
|
CN110896634A
(zh)
|
2017-07-03 |
2020-03-20 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物
|
CA3069524A1
(en)
|
2017-07-14 |
2019-01-17 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
EP3431088A1
(de)
*
|
2017-07-20 |
2019-01-23 |
Paris Sciences et Lettres - Quartier Latin |
Mntbap zur induktion einer transienten immuntoleranz
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
WO2019023624A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
|
US20210206882A1
(en)
*
|
2017-08-01 |
2021-07-08 |
Ab Studio Inc. |
Bispecific antibodies and uses thereof
|
AU2018309339A1
(en)
|
2017-08-04 |
2020-02-20 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
MX2020001793A
(es)
|
2017-08-17 |
2020-07-22 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
|
WO2019035985A1
(en)
|
2017-08-18 |
2019-02-21 |
Tragara Pharmaceuticals, Inc. |
POLYMORPHIC FORM OF TG02
|
BR112020003533A2
(pt)
|
2017-08-25 |
2020-11-17 |
Five Prime Therapeutics, Inc. |
anticorpos b7-h4 e métodos de uso dos mesmos
|
WO2019046321A1
(en)
|
2017-08-28 |
2019-03-07 |
Bristol-Myers Squibb Company |
TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
EP3684413A1
(de)
|
2017-09-20 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Dosierungsschema für kombinationstherapie unter verwendung von pd-1-achse-bindenden antagonisten und gegen gpc3 gerichteten wirkstoff
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
AU2018338314A1
(en)
|
2017-09-22 |
2020-04-09 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
US11304952B2
(en)
|
2017-09-25 |
2022-04-19 |
Chemocentryx, Inc. |
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
|
AU2018338647A1
(en)
*
|
2017-09-27 |
2020-05-07 |
University Of Southern California |
Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
|
KR20200086664A
(ko)
|
2017-09-30 |
2020-07-17 |
테사로, 인코포레이티드 |
암을 치료하기 위한 조합 요법
|
WO2019071123A1
(en)
|
2017-10-06 |
2019-04-11 |
Tesaro, Inc. |
POLYRHEERAPIES AND USES THEREOF
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN111225926A
(zh)
*
|
2017-10-10 |
2020-06-02 |
努玛治疗有限公司 |
靶向pdl1的抗体及其使用方法
|
EP3470426A1
(de)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispezifischer antikörper
|
AU2018348431A1
(en)
|
2017-10-10 |
2020-03-12 |
Numab Therapeutics AG |
Antibodies targeting CD137 and methods of use thereof
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
SG11202002982YA
(en)
|
2017-10-10 |
2020-04-29 |
Numab Therapeutics AG |
Multispecific antibody
|
EP3470429A1
(de)
*
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon
|
EP3694545A4
(de)
*
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
|
SG11202003341UA
(en)
|
2017-10-13 |
2020-05-28 |
Harpoon Therapeutics Inc |
B cell maturation antigen binding proteins
|
JP7395471B2
(ja)
|
2017-10-13 |
2023-12-11 |
オーセ イミュノセラピューティクス |
改変抗SIRPa抗体及びその使用
|
US20200254091A1
(en)
|
2017-10-13 |
2020-08-13 |
Merck Patent Gmbh |
Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
|
EP3694884A1
(de)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Verfahren zur behandlung von tumoren
|
WO2019077062A1
(en)
|
2017-10-18 |
2019-04-25 |
Vivia Biotech, S.L. |
C-CELLS ACTIVATED BY BIT
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
SG11202003486UA
(en)
|
2017-10-19 |
2020-05-28 |
Debiopharm Int Sa |
Combination product for the treatment of cancer
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019089921A1
(en)
|
2017-11-01 |
2019-05-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
ES2925450T3
(es)
|
2017-11-06 |
2022-10-18 |
Bristol Myers Squibb Co |
Compuestos de isofuranona útiles como inhibidores de HPK1
|
JP2021502344A
(ja)
|
2017-11-06 |
2021-01-28 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
RU2754131C1
(ru)
|
2017-11-14 |
2021-08-27 |
Пфайзер Инк. |
Комбинированная терапия ингибитором ezh2
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
US11696936B2
(en)
|
2017-11-27 |
2023-07-11 |
Ose Immunotherapeutics |
Treatment of cancer
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
EP3727463A1
(de)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepin-antikörper-konjugate
|
JP2021508703A
(ja)
|
2017-12-26 |
2021-03-11 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
CN111788227A
(zh)
|
2017-12-27 |
2020-10-16 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
TW201930350A
(zh)
*
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス, インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
EP3735590A1
(de)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von resistentem melanom
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11154556B2
(en)
|
2018-01-08 |
2021-10-26 |
Chemocentryx, Inc. |
Methods of treating solid tumors with CCR2 antagonists
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
EP3737408A1
(de)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immunstimulierende rnas zur kombination mit einer chimären antigen-rezeptor-therapie
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3737689A4
(de)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
|
KR20200108306A
(ko)
|
2018-01-10 |
2020-09-17 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
Pd-l1 항체 또는 이의 항원-결합 단편, 및 이의 약학적 용도
|
EP3737696A1
(de)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Kombinationstherapie mit anti-il-8-antikörpern und anti-pd-1-antikörpern zur behandlung von krebs
|
EP3737675A4
(de)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn-liganden und verwendungen davon
|
EP3737666A4
(de)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Proteinabbaumittel und verwendungen davon
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US20210363242A1
(en)
|
2018-01-16 |
2021-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
US20210038559A1
(en)
|
2018-01-22 |
2021-02-11 |
Thomas Richard Gadek |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
MX2020007526A
(es)
|
2018-01-22 |
2020-09-09 |
Bristol Myers Squibb Co |
Composiciones y metodos para tratar el cancer.
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Gcn2阻害剤およびその使用
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
EP3746116A1
(de)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Kombinationstherapie unter verwendung eines chimären antigenrezeptors
|
CN112533613A
(zh)
|
2018-02-06 |
2021-03-19 |
通用医疗公司 |
作为肿瘤免疫应答的生物标志物的重复rna
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
EP3752203A1
(de)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
EP3759110A1
(de)
|
2018-02-28 |
2021-01-06 |
Novartis AG |
Indol-2-carbonylverbindungen und ihre verwendung zur behandlung von hepatitis b
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
CA3093742A1
(en)
|
2018-03-12 |
2019-09-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
EP3765512A1
(de)
|
2018-03-13 |
2021-01-20 |
OSE Immunotherapeutics |
Verwendung von anti-humanen sirpa-v1-antikörpern und verfahren zur herstellung von anti-sirpa-v1-antikörpern
|
KR20200131270A
(ko)
|
2018-03-14 |
2020-11-23 |
메르크 파텐트 게엠베하 |
대상체에서의 암을 치료하기 위한 화합물 및 이의 용도
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
JP7037218B2
(ja)
|
2018-03-14 |
2022-03-16 |
サーフィス オンコロジー インコーポレイテッド |
Cd39と結合する抗体及びその使用
|
MX2020009743A
(es)
*
|
2018-03-19 |
2020-10-08 |
Abeome Corp |
Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
|
CA3092589A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2019183551A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
US11976128B2
(en)
|
2018-03-23 |
2024-05-07 |
Board Of Regents, The University Of Texas System |
Human PD-L2 antibodies and methods of use therefor
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
WO2019190327A2
(en)
|
2018-03-30 |
2019-10-03 |
Merus N.V. |
Multivalent antibody
|
US20210155703A1
(en)
|
2018-04-04 |
2021-05-27 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3781162A1
(de)
|
2018-04-16 |
2021-02-24 |
Arrys Therapeutics, Inc. |
Ep4-inhibitoren und verwendung davon
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
CN112105645A
(zh)
|
2018-04-18 |
2020-12-18 |
Xencor股份有限公司 |
Il-15/il-15ra异二聚体fc融合蛋白及其用途
|
EP3781599A1
(de)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Auf pd-1 abgezielte heterodimere fusionsproteine mit il-15-/il-15ra-fc-fusionsproteinen und pd-1-antigen-bindenden domänen und verwendungen davon
|
WO2019204743A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
PE20210160A1
(es)
|
2018-04-25 |
2021-01-26 |
Innate Tumor Immunity Inc |
Moduladores de nlrp3
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
US20210246208A1
(en)
|
2018-05-04 |
2021-08-12 |
Merck Patent Gmbh |
Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancer
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
US20190365719A1
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
|
JP2021525769A
(ja)
|
2018-06-01 |
2021-09-27 |
ノバルティス アーゲー |
Cd123及びcd3に結合する二重特異性抗体の投与
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
AU2019290212A1
(en)
*
|
2018-06-22 |
2021-02-04 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer using combination therapy
|
BR112020026568A2
(pt)
|
2018-06-27 |
2021-03-23 |
Bristol-Myers Squibb Company |
Compostos de naftiridinona úteis como ativadores de célula t
|
US10669272B2
(en)
|
2018-06-27 |
2020-06-02 |
Bristol-Myers Squibb Company |
Substituted naphthyridinone compounds useful as T cell activators
|
KR102216576B1
(ko)
*
|
2018-06-29 |
2021-02-17 |
국민대학교 산학협력단 |
Pd-1과 결합력이 증가된 pd-l1 변이체
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
BR112021000332A2
(pt)
|
2018-07-09 |
2021-04-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos químicos
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020012334A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
KR20210031722A
(ko)
|
2018-07-11 |
2021-03-22 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
US20210147549A1
(en)
*
|
2018-07-11 |
2021-05-20 |
Momenta Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
SG11202100373VA
(en)
|
2018-07-20 |
2021-02-25 |
Surface Oncology Inc |
Anti-cd112r compositions and methods
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
US20210238287A1
(en)
|
2018-07-26 |
2021-08-05 |
Bristol-Myers Squibb Company |
LAG-3 Combination Therapy for the Treatment of Cancer
|
WO2020027224A1
(ja)
|
2018-07-31 |
2020-02-06 |
国立大学法人東京大学 |
新たな結合特異性を抗体に付与する超汎用法
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CN112996567A
(zh)
|
2018-08-16 |
2021-06-18 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂
|
SG11202101486RA
(en)
|
2018-08-16 |
2021-03-30 |
Innate Tumor Immunity Inc |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
TWI803682B
(zh)
|
2018-08-20 |
2023-06-01 |
美商輝瑞股份有限公司 |
抗-gdf15抗體、組成物及使用方法
|
SG11202101757QA
(en)
*
|
2018-08-20 |
2021-03-30 |
1Globe Biomedical Co Ltd |
Novel cancer immunotherapy antibody compositions
|
KR20210052468A
(ko)
|
2018-08-27 |
2021-05-10 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137/her2 이중특이적 제제 및 pd-1 축 억제제를 포함하는 조합물 치료요법 및 이의 용도
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
US11331269B2
(en)
|
2018-09-06 |
2022-05-17 |
Massachusetts Institute Of Technology |
Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
|
KR20210056378A
(ko)
*
|
2018-09-07 |
2021-05-18 |
더 제너럴 하스피탈 코포레이션 |
면역 체크포인트 억제를 위한 조성물 및 방법
|
EP3846793B1
(de)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e-inhibitoren und verwendungen davon
|
WO2020053654A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
CN109053891B
(zh)
*
|
2018-09-17 |
2021-12-21 |
苏州泓迅生物科技股份有限公司 |
一种抗pd-l1抗体及其制备方法和应用
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
EP3852524B1
(de)
|
2018-09-20 |
2023-06-28 |
Iovance Biotherapeutics, Inc. |
Expansion von tils aus kryokonservierten tumorproben
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
WO2020064971A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
AU2019346645A1
(en)
|
2018-09-27 |
2021-04-29 |
Marengo Therapeutics, Inc. |
CSF1R/CCR2 multispecific antibodies
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
CN112839962A
(zh)
|
2018-10-09 |
2021-05-25 |
百时美施贵宝公司 |
用于治疗癌症的抗mertk抗体
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
EP3867409A1
(de)
|
2018-10-16 |
2021-08-25 |
Novartis AG |
Tumormutationslast allein oder in kombination mit immunmarkern als biomarker zur vorhersage des ansprechens auf eine gezielte therapie
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CN113286611A
(zh)
|
2018-10-19 |
2021-08-20 |
百时美施贵宝公司 |
用于黑色素瘤的组合疗法
|
MX2021004603A
(es)
|
2018-10-22 |
2021-09-08 |
Glaxosmithkline Ip Dev Ltd |
Dosificacion.
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
EA202191175A1
(ru)
|
2018-10-29 |
2021-09-08 |
Мерсана Терапьютикс, Инк. |
Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
AU2019372436A1
(en)
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
JP2022505925A
(ja)
|
2018-11-01 |
2022-01-14 |
メルク パテント ゲーエムベーハー |
抗tim-3抗体
|
WO2020095183A1
(en)
|
2018-11-05 |
2020-05-14 |
Pfizer Inc. |
Combination for treating cancer
|
WO2020095184A1
(en)
|
2018-11-05 |
2020-05-14 |
Pfizer Inc. |
Combinations for treating cancer
|
MA54139A
(fr)
|
2018-11-06 |
2021-09-15 |
BioNTech SE |
Formulation d'anticorps
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
WO2020094122A1
(zh)
|
2018-11-09 |
2020-05-14 |
江苏恒瑞医药股份有限公司 |
一种TGF-β受体融合蛋白药物组合物及其用途
|
WO2020099230A1
(en)
|
2018-11-14 |
2020-05-22 |
Bayer Aktiengesellschaft |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
WO2020102375A1
(en)
|
2018-11-14 |
2020-05-22 |
Regeneron Pharmaceuticals, Inc. |
Intralesional administration of pd-1 inhibitors for treating skin cancer
|
JP2022507606A
(ja)
|
2018-11-16 |
2022-01-18 |
ネオイミューンテック, インコーポレイテッド |
Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
EP3883610A4
(de)
|
2018-11-20 |
2022-11-02 |
Cornell University |
Makrocyclische komplexe von radionukliden und deren verwendung in der radiotherapie von krebs
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020104496A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
EP3886842A1
(de)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Kombinationsbehandlung von hiv-infektionen
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
EP4342473A3
(de)
|
2018-11-30 |
2024-05-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Verbindungen zur verwendung in der hiv-therapie
|
EP3890749A4
(de)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9-inhibitoren und polymorphe davon zur verwendung als mittel zur behandlung von krebs
|
KR20210098504A
(ko)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
WO2020127059A1
(en)
|
2018-12-17 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
US20220064332A1
(en)
|
2018-12-19 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
EP3670659A1
(de)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarker und verwendungen bei der behandlung von viralen infektionen, entzündlichen oder krebserkrankungen
|
EP3897853A1
(de)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Zielgerichtete heterodimere fc-fusionsproteine mit il-15/il-15ra und nkg2d-antigenbindenden domänen
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
CA3118182A1
(en)
|
2018-12-21 |
2020-06-25 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
EP3898674A1
(de)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Verwendung von il-1beta-bindenden antikörpern
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
BR112021011351A2
(pt)
|
2018-12-21 |
2021-11-16 |
Novartis Ag |
Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
WO2020136235A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene Sa |
M2-defective poxvirus
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
CN113301962A
(zh)
|
2019-01-14 |
2021-08-24 |
先天肿瘤免疫公司 |
用于治疗癌症的杂环nlrp3调节剂
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Nlrp3モジュレーター
|
WO2020150113A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
AU2020208909A1
(en)
|
2019-01-15 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
|
EP3918332A1
(de)
|
2019-01-30 |
2021-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur bestimmung, ob eine an krebs leidende person eine reaktion mit einem immun-checkpoint-inhibitor erreicht
|
CN113365659B
(zh)
*
|
2019-01-31 |
2023-08-18 |
正大天晴药业集团股份有限公司 |
抗pd-l1抗体治疗头颈癌的用途
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
US20220098674A1
(en)
|
2019-02-13 |
2022-03-31 |
Inserm (Institut National De La Santé Et Dr La Recherch Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CA3129585A1
(en)
*
|
2019-02-18 |
2020-08-27 |
Medivir Aktiebolag |
Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
CN113710270A
(zh)
|
2019-02-19 |
2021-11-26 |
迈斯特治疗公司 |
产生可用于治疗癌症的自体t细胞的方法及其组合物
|
CA3130807A1
(en)
*
|
2019-02-21 |
2020-08-27 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-pd-l1 antibody and use thereof
|
MX2021010228A
(es)
|
2019-02-28 |
2021-10-26 |
Regeneron Pharma |
Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
|
MX2021010560A
(es)
|
2019-03-06 |
2021-11-12 |
Regeneron Pharma |
Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
|
SG11202109066RA
(en)
|
2019-03-19 |
2021-09-29 |
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
MX2021011753A
(es)
|
2019-03-26 |
2022-01-31 |
Univ Michigan Regents |
Degradadores de moleculas peque?as de stat3.
|
JP2022527177A
(ja)
|
2019-03-28 |
2022-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
EP3946628A1
(de)
|
2019-03-28 |
2022-02-09 |
Bristol-Myers Squibb Company |
Verfahren zur behandlung eines tumors
|
EP3947403A1
(de)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3-protein-abbauer
|
WO2020205662A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Inc. |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(zh)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
SG11202109441UA
(en)
|
2019-04-12 |
2021-09-29 |
Vascular Biogenics Ltd |
Methods of anti-tumor therapy
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
US11208486B2
(en)
*
|
2019-04-26 |
2021-12-28 |
I-Mab Biopharma Us Limited |
Human PD-L1 antibodies
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
AU2020267491A1
(en)
*
|
2019-05-06 |
2021-12-02 |
Brown University |
Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
|
AU2020281535A1
(en)
|
2019-05-24 |
2022-01-27 |
Merck Patent Gmbh |
Combination therapies using CDK inhibitors
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
WO2020248926A1
(zh)
*
|
2019-06-10 |
2020-12-17 |
山东博安生物技术有限公司 |
抗PDL1和TGFβ的双功能融合蛋白及其用途
|
CN114269715A
(zh)
|
2019-06-12 |
2022-04-01 |
范德比尔特大学 |
作为氨基酸转运抑制剂的二苄基胺
|
WO2020249071A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
|
WO2020252353A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
CN114127073B
(zh)
|
2019-07-16 |
2024-05-31 |
密歇根大学董事会 |
作为eed抑制剂的咪唑并嘧啶和其用途
|
EP3999534A4
(de)
*
|
2019-07-19 |
2023-02-08 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Neuer anti-pd-l1-antikörper gegen cd98 und verwendung davon
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
AU2020336381A1
(en)
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
CA3149621A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
AU2020348849A1
(en)
|
2019-09-19 |
2022-04-07 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
AU2020350689A1
(en)
|
2019-09-19 |
2022-03-31 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
AU2020350137A1
(en)
|
2019-09-20 |
2022-04-28 |
Merck Patent Gmbh |
Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody
|
EP4031873A1
(de)
|
2019-09-22 |
2022-07-27 |
Bristol-Myers Squibb Company |
Quantitative räumliche profilierung für lag-3 -antagonistentherapie
|
CA3152263A1
(en)
|
2019-09-25 |
2021-04-01 |
Julia SANTUCCI PEREIRA DEL BUONO |
Composite biomarker for cancer therapy
|
KR20220066346A
(ko)
|
2019-09-25 |
2022-05-24 |
서피스 온콜로지, 인크. |
항-il-27 항체 및 이의 용도
|
AU2020353055B2
(en)
|
2019-09-26 |
2024-03-07 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
AU2020355614A1
(en)
|
2019-09-27 |
2022-04-14 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
EP3800201A1
(de)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
|
WO2021067863A2
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
EP4037714A1
(de)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur modulation von makrophagen-polarisation
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
CN114786682A
(zh)
|
2019-10-14 |
2022-07-22 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
WO2021074391A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
AU2020372478A1
(en)
|
2019-10-23 |
2022-06-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
EP4049675A4
(de)
|
2019-10-25 |
2023-11-22 |
Daiichi Sankyo Company, Limited |
Kombination von anti-garp-antikörper und immunregulator
|
EP4051286A1
(de)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und zusammensetzungen zur behandlung von uvealem melanom
|
TW202132329A
(zh)
|
2019-11-04 |
2021-09-01 |
美商阿列克特有限責任公司 |
Siglec-9 ecd融合分子及其使用方法
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
MX2022005474A
(es)
|
2019-11-08 |
2022-06-02 |
Bristol Myers Squibb Co |
Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
AU2020387392A1
(en)
|
2019-11-19 |
2022-07-14 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
CA3159071A1
(en)
|
2019-11-26 |
2021-06-03 |
Tamar I. ROSENBAUM |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
CN115279764A
(zh)
|
2019-11-26 |
2022-11-01 |
医肯纳肿瘤学公司 |
多晶型咔唑衍生物及其用途
|
JPWO2021106978A1
(de)
|
2019-11-27 |
2021-06-03 |
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
A method for producing tumor-reactive t cells using modulatory substances
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2023510108A
(ja)
|
2019-12-19 |
2023-03-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
Dgk阻害剤およびチェックポイントアンタゴニストの組み合わせ
|
WO2021123243A1
(en)
|
2019-12-19 |
2021-06-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
AU2020412698A1
(en)
|
2019-12-23 |
2022-08-18 |
Bristol-Myers Squibb Company |
Substituted piperazine derivatives useful as T cell activators
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
CA3162985A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted quinazolinyl compounds useful as t cell activators
|
US20230086933A1
(en)
|
2019-12-23 |
2023-03-23 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
IL294269A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substitute quinolinyl piperazine compounds are useful as t-cell activators
|
EP4081308A4
(de)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics Inc |
Smarca-degrader und verwendungen davon
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
US20230045791A1
(en)
|
2020-01-06 |
2023-02-16 |
Hifibio (Hk) Limited |
Anti-tnfr2 antibody and uses thereof
|
CN115210261A
(zh)
|
2020-01-07 |
2022-10-18 |
高诚生物医药(香港)有限公司 |
抗半乳糖凝集素-9抗体及其用途
|
CN115279400A
(zh)
|
2020-01-10 |
2022-11-01 |
布里格姆妇女医院 |
用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
CN115279771A
(zh)
|
2020-01-15 |
2022-11-01 |
缆图药品公司 |
Map4k1抑制剂
|
EP4090770A1
(de)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von melanom
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
IL294368A
(en)
|
2020-01-29 |
2022-08-01 |
Merus Nv |
Means and method for modulating mixed effects in immune cells
|
US20230086099A1
(en)
|
2020-01-30 |
2023-03-23 |
Ona Therapeutics, S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
US20230072528A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
EP4100426A1
(de)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 und verwendungen davon
|
EP4106788A1
(de)
|
2020-02-18 |
2022-12-28 |
Alector LLC |
Pilra-antikörper und verfahren zur verwendung davon
|
CA3172902A1
(en)
|
2020-02-27 |
2021-09-02 |
Myst Therapeutics, Llc |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合cd123和cd3之雙特異性抗體的給藥
|
EP4110407A1
(de)
|
2020-02-28 |
2023-01-04 |
Bristol-Myers Squibb Company |
Radioaktiv markierte fibronectinbasierte gerüste und antikörper sowie therapeutische verwendungen davon
|
EP4110955A1
(de)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur diagnose, prognose und verwaltung der behandlung von brustkrebs
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
KR20220151195A
(ko)
|
2020-03-06 |
2022-11-14 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
AU2021230575A1
(en)
|
2020-03-06 |
2022-10-20 |
Celgene Quanticel Research, Inc. |
Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or sqNSCLC
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
EP3878446A1
(de)
|
2020-03-09 |
2021-09-15 |
Universite De Geneve |
Hsd11b1-inhibitoren zur verwendung in der immuntherapie und verwendungen davon
|
US11407712B2
(en)
|
2020-03-19 |
2022-08-09 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
|
CN115776887A
(zh)
|
2020-03-19 |
2023-03-10 |
凯麦拉医疗公司 |
Mdm2降解剂和其用途
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
IL296673A
(en)
|
2020-03-23 |
2022-11-01 |
Bristol Myers Squibb Co |
Anti-ccr8 antibodies for cancer treatment
|
US20230159573A1
(en)
|
2020-03-26 |
2023-05-25 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
EP4132971A1
(de)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinitätsgereifte anti-lap-antikörper und verwendungen davon
|
EP4136105A1
(de)
|
2020-04-14 |
2023-02-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlung für krebs auf basis eines icos-antikörpers und eines pd-l1-antikörper-tgf-beta-rezeptor-fusionsproteins
|
WO2021216920A1
(en)
|
2020-04-22 |
2021-10-28 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
JP2023524257A
(ja)
|
2020-05-05 |
2023-06-09 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸阻害剤に対する応答の予測
|
JP2023526723A
(ja)
|
2020-05-12 |
2023-06-23 |
キュー バイオファーマ, インコーポレイテッド |
多量体t細胞調節性ポリペプチド及びその使用方法
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
KR20230015954A
(ko)
|
2020-05-26 |
2023-01-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
|
CA3184802A1
(en)
|
2020-05-26 |
2021-12-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
EP4157319A1
(de)
|
2020-05-28 |
2023-04-05 |
Modernatx, Inc. |
Verwendung von mrnas kodierend für ox40l, il-23 und il-36gamma zur behandlung von krebs
|
IL298111A
(en)
|
2020-06-02 |
2023-01-01 |
Arcus Biosciences Inc |
Antibodies to tigit
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2022003554A1
(en)
|
2020-07-01 |
2022-01-06 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
WO2022023379A1
(en)
|
2020-07-28 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for preventing and treating a cancer
|
IL300175A
(en)
|
2020-07-30 |
2023-03-01 |
Kymera Therapeutics Inc |
Methods for treating mutant lymphomas
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
US20230303695A1
(en)
|
2020-08-10 |
2023-09-28 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
JP2023540217A
(ja)
|
2020-08-26 |
2023-09-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Pd-1阻害剤を投与することによりがんを処置する方法
|
EP4204458A1
(de)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Verfahren zum nachweis von trbc1 oder trbc2
|
EP4204095A1
(de)
|
2020-08-28 |
2023-07-05 |
Bristol-Myers Squibb Company |
Lag-3-antagonistentherapie für leberzellkarzinom
|
CN111808196B
(zh)
*
|
2020-08-31 |
2020-12-29 |
北京百奥赛图基因生物技术有限公司 |
抗pd-1抗体及其用途
|
JP2023538955A
(ja)
|
2020-08-31 |
2023-09-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在シグネチャーおよび免疫療法
|
AU2021337650A1
(en)
|
2020-09-03 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
TW202227126A
(zh)
|
2020-09-14 |
2022-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
異源初免加強疫苗
|
CN111920948B
(zh)
*
|
2020-09-25 |
2021-02-02 |
安可瑞(山西)生物细胞有限公司 |
包含免疫细胞的药物组合物用于治疗癌症
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
KR20230093282A
(ko)
|
2020-10-23 |
2023-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 lag-3 길항제 요법
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
EP4236960A1
(de)
|
2020-10-28 |
2023-09-06 |
Ikena Oncology, Inc. |
Kombination eines ahr-hemmers mit einem pdx-hemmer oder doxorubicin
|
EP3992208A1
(de)
*
|
2020-11-03 |
2022-05-04 |
Randox Laboratories Ltd |
Anti-pd-l1 vhh antikörper
|
JP2023548529A
(ja)
|
2020-11-06 |
2023-11-17 |
ノバルティス アーゲー |
Cd19結合分子及びその使用
|
WO2022101302A1
(en)
|
2020-11-12 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
EP4244392A1
(de)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
|
EP4244391A1
(de)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255895A1
(de)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead-hemmer und verwendungen davon
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
AU2021400725A1
(en)
|
2020-12-16 |
2023-08-03 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Pd1/pd-l1抗体の皮下投与
|
IL303648A
(en)
|
2020-12-28 |
2023-08-01 |
Bristol Myers Squibb Co |
Antibody preparations and methods of using them
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
JP2024502189A
(ja)
|
2021-01-11 |
2024-01-17 |
バイシクルティーエクス・リミテッド |
癌を処置する方法
|
EP4282413A1
(de)
|
2021-01-21 |
2023-11-29 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Zusammensetzung und verfahren zur behandlung von tumoren
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
WO2022171121A1
(zh)
|
2021-02-10 |
2022-08-18 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
JP2024506339A
(ja)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
AU2022230795A1
(en)
|
2021-03-02 |
2023-09-21 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
US20240166647A1
(en)
|
2021-03-03 |
2024-05-23 |
The Regents Of The University Of Michigan |
Cereblon Ligands
|
JP2024510947A
(ja)
|
2021-03-05 |
2024-03-12 |
レアダルティス、ソシエダッド リミターダ |
三量体ポリペプチドおよびがん治療におけるその使用
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
US20240199648A1
(en)
|
2021-03-08 |
2024-06-20 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
CA3170902A1
(en)
|
2021-03-23 |
2022-09-23 |
Jigar Desai |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
EP4314060A1
(de)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigenbindende proteine und kombinationen davon
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
TW202304881A
(zh)
|
2021-04-06 |
2023-02-01 |
美商必治妥美雅史谷比公司 |
經吡啶基取代之側氧基異吲哚啉化合物
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
JP2024515263A
(ja)
|
2021-04-09 |
2024-04-08 |
オーエスイー・イミュノセラピューティクス |
改善された特性を有する二機能性分子のための新規足場構造
|
PE20240327A1
(es)
|
2021-04-13 |
2024-02-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
|
EP4322938A1
(de)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neues verfahren zur verbesserung der zytotoxizität von nk-zellen
|
EP4323066A1
(de)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek-hemmer und verwendungen davon
|
US20240158861A1
(en)
|
2021-04-23 |
2024-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
CA3219336A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022242737A1
(zh)
|
2021-05-21 |
2022-11-24 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
WO2022246177A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl compounds
|
WO2022246179A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
AU2022281461A1
(en)
|
2021-05-25 |
2024-01-04 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
CN117396512A
(zh)
|
2021-05-26 |
2024-01-12 |
分子免疫中心 |
治疗组合物用于治疗上皮源性肿瘤患者的用途
|
BR112023025194A2
(pt)
|
2021-06-04 |
2024-02-27 |
Boehringer Ingelheim Int |
Anticorpos anti-sirp-alfa
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
AR126442A1
(es)
|
2021-07-14 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
WO2023288264A1
(en)
|
2021-07-15 |
2023-01-19 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
EP4373505A1
(de)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Kombination von checkpoint-inhibitoren und einem onkolytischen virus zur behandlung von krebs
|
KR20240042476A
(ko)
|
2021-07-30 |
2024-04-02 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
CN118043352A
(zh)
|
2021-09-02 |
2024-05-14 |
德国癌症研究中心公共法律基金会 |
副作用减少的抗cecam6抗体
|
CN118201914A
(zh)
|
2021-09-08 |
2024-06-14 |
雷多纳治疗公司 |
Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
AU2022377637A1
(en)
|
2021-10-28 |
2024-05-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
CA3224890A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023079430A1
(en)
|
2021-11-02 |
2023-05-11 |
Pfizer Inc. |
Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
CA3238660A1
(en)
|
2021-11-17 |
2023-05-25 |
Institut National De La Sante Et De La Recherche Medicale |
Universal sarbecovirus vaccines
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
WO2023159102A1
(en)
|
2022-02-17 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
US20240117030A1
(en)
|
2022-03-03 |
2024-04-11 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
KR20230130911A
(ko)
|
2022-03-04 |
2023-09-12 |
주식회사 온코인사이트 |
암 예방 또는 치료를 위한 병용 투여용 약학 조성물
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023213763A1
(en)
*
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
WO2023213764A1
(en)
*
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024094688A1
(en)
|
2022-11-01 |
2024-05-10 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
WO2024097328A1
(en)
|
2022-11-03 |
2024-05-10 |
Incyte Corporation |
Combination therapies comprising an anti-gitr antibody for treating cancers
|
WO2024102635A1
(en)
|
2022-11-07 |
2024-05-16 |
Alector Llc |
Uses of siglec-9 ecd fusion molecules in cancer treatment
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
CN116077645A
(zh)
*
|
2022-12-28 |
2023-05-09 |
广州誉衡生物科技有限公司 |
抗-pd-1抗体及其在制备治疗非小细胞肺癌患者的药物中的用途
|